May 1, 2020
CBMG to Report 1st Quarter 2020 Results on May 6th, 2020
NEW YORK, NY and SHANGHAI, China, May 1, 2020 – Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the first quarter ended March 31, 2020 after the market closes on Wednesday May 6th, 2020.
The Company will host a conference call and webcast with the investment community on Wednesday May 6th at 5:00 P.M. Eastern Time featuring remarks by Tony Liu, CEO, CFO, Executive Director of CBMG.
What: Cellular Biomedicine Group First Quarter 2020 Results Conference Call
Date: Wednesday, May 6, 2020
Time: 5:00 p.m. Eastern Time
Live Call: Toll-Free: +1-833-423-0438
China: +86 800-870-0169 or +86 400-682-8609
Conference ID: 7690079
Toll-Free: (855) 859-2056
International: (404) 537-3406
Conference ID: 7690079
(Available approximately two hours after the completion of the live call until 8:00 p.m. ET on May 20, 2020)
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. It conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company’s GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a “Joint Laboratory of Cell Therapy” with GE Healthcare and a “Joint Cell Therapy Technology Innovation and Application Center” with Thermo Fisher Scientific, which partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) approved the Company’s IND application for a Phase II trial for AlloJoin®, CBMG’s “Off-the-Shelf” allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and has accepted the Company’s IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Derrick C. Li
Head of Strategy and Investor Relations, CBMG